Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (279)	4/16/1998 4:16:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 717

Hi squetch, <<Do you think the ASCO presentation will be more follow up from info in 10/20/97 press release?>> I don't see how it can be much more than that, although hopefully they will include preliminary data on the 21 new patients treated. It can't be more than preliminary, as they only enrolled the last patient in March. <<Do you know when they expect to present the PII data or issue info on results?>> All I know is that their last press release said that: "The phase Ib/II trial should provide the data needed to initiate the phase III trial, expected to begin in mid-1998". Presumably they will anounce the results of the Phase II before starting the Phase III. <<I am of the opinion that that data will put them on the map, but will obviously depend on the results.>> I think the actual move into Phase III and the start of all the NCI trials will be what does it. Their data was already pretty convincing. <<Will the ANTRIN PI info come out in the next 6 months also?>> No idea. One of the research reports I read seemed to think this was very much a Phase I - i.e. not to expect any efficacy data, although I don't know why not. << Gadolite??>> This will take at least 18 months .... <G> <<Peter you are aware that there are cancer drugs selling in the hundreds of millions of dollars a year?>> Well 700,000 patients a year get radiation treatment. Nothing I've seen to date contradicts the notion that they should _all_ get Gd-Tex (none of the analysts say this, though). Some patients might just get a lower radiation dose for the same effect on the tumor. The research reports used $2000 per treatment, saying they were being conservative. That gives you a whole 'nother decimal place than the other cancer drugs. <<If you don't respond, I will know the men in white suits have come to take you home.(:>)>> They're very progressive in this institution - they even let the patients have internet access <G> Peter